GVB Biopharma, a subsidiary of 22nd Century Group, has opened a distribution facility in the Netherlands to support its growing business in Europe, the Middle East, and Africa. The new facility will increase access to GVB's cannabis/marijuana products for customers, expedite transactions, and optimize cross-border tax and customs treatment.
The company stated that the recent increase in GVB's manufacturing capabilities in the United States coincides with the emergence of the company's distribution facilities in the Netherlands. Some of the additional production capacity has been designated to meet the growing demand in the European market, where profit margins are higher than in the United States.
James A. Mish, CEO of 22nd Century Group, said in a statement, "We are pleased to expand our business operations in Europe, allowing our customers and partners to access high-quality products more efficiently.
Our new distribution facility in Holland allows us to shorten delivery times to our partners by half and serve our rapidly growing customer base with high-quality extracts and isolates. The cannabis industry in Europe is expanding rapidly and is expected to reach €3.2 billion [$3.33 billion] by 2025. Our new facility will enable us to capture more market share, expand our business, and reach a larger customer base in the region.
Statement:
This article is compiled from third-party information and is intended for industry exchange and learning purposes only.
This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the content. The translation of this article is solely for the purpose of industry communication and research.
Due to limitations in translation ability, the translated article may not fully capture the original text. Please refer to the original text for accurate information.
2FIRSTS is fully aligned with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and foreign-related statements and positions.
The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
